Table 2. The patient demographics and baseline characteristics.
| Author, Year | Groups | Race, n (%) | Bodyweight (kg) | eGFRc (mL/min/1.73 m2) | CKD stage |
|---|---|---|---|---|---|
| Akizawa et al. 2019 [32] | Roxadustat | Japanese 80 (100%) | 59.07 ± 9.83 | 16.3 ± 7.8 | 2 to 5 |
| Placebo | Japanese 27 (100%) | 60.17 ± 8.72 | 16.3 ± 8.5 | ||
| Akizawa et al. 2021 [14] | Roxadustat | Japanese 131 (100%) | N/A | 17.9 ± 8.2 | N/A |
| DA | Japanese 131 (100%) | N/A | 18.2 ± 8.8 | ||
| Barratt et al. 2021 [15] | Roxadustat | White 306 (94.7%), Black 8 (2.5%), Asian 9 (2.8%) | 76.90 ± 16.33 | 20.31 ± 11.49 | 3 to 5 |
| DA | White 281 (95.9%), Black 2 (0.7%), Asian 10 (3.4%) | 78.39 ± 17.68 | 20.34 ± 10.73 | ||
| Besarab et al. 2015 [33] | Roxadustat | White 49 (55.7%), Black 34 (38.6%), Asian 2 (2.3%) | N/A | 34.3 ± 12.7 | 3 to 4 |
| Placebo | White 15 (53.6%), black 11 (39.3%), Asian 2 (7.1%) | N/A | 31.4 ± 12.4 | ||
| Chen et al. 2017 [29] | Roxadustat | Chinese 61 (100%) | 57.4 ± 11 | 19.4 ± 9.5 | 1 to 4 |
| Placebo | Chinese 30 (100%) | 56.9 ±10.3 | 23.0 ±13.4 | ||
| Chen et al. 2019 [30] | Roxadustat | N/A | N/A | 16.5 ± 8 | 3 to 5 |
| Placebo | N/A | N/A | 14.5 ± 7.6 | ||
| Coyne et al. 2021 [28] | Roxadustat | N/A | N/A | 21.9 ± 11.5 | 3 to 5 |
| Placebo | N/A | N/A | 22.4 ± 11.4 | ||
| Fishbane et al. 2021 [34] | Roxadustat | White 623 (45%), Black 112 (8.1%), Asian 544 (39.3%), American Indian 24 (1.7%) | 69.9 ± 18.5 | 19.7 ± 11.7 | 3 to 5 |
| Placebo | White 611 (44.4%), Black 115(8.4%), Asian 538 (39.1%), American Indian 29 (2.1%), Native Hawaiian 2 (0.1%) | 70.6 ± 18.8 | 20 ± 11.7 | ||
| Shutov et al. 2021 [16] | Roxadustat | White 335 (85.7%), Black 10 (2.6%), Asian 9 (2.3%) | 73.86 ± 16.49 | 16.5 ± 10.2 | 3 to 5 |
| Placebo | White 182 (89.7%), Black 3 (1.5%) | 76.50 ± 16.51 | 17.2 ± 11.7 |
Continuous variables are expressed in mean ± standard deviation.
DA = darbepoetin alfa; eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease; CPN = chronic pyelonephritis; PKD = Polycystic kidney disease; N/A = not applicable.